Novo Nordisk A/S (NYSE:NVO) Shares Sold by AMG National Trust Bank

AMG National Trust Bank trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 51.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,436 shares of the company’s stock after selling 4,754 shares during the quarter. AMG National Trust Bank’s holdings in Novo Nordisk A/S were worth $382,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $28,000. Center for Financial Planning Inc. raised its stake in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $42,000. Dunhill Financial LLC raised its stake in Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after acquiring an additional 311 shares in the last quarter. Finally, Albion Financial Group UT raised its stake in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of several research analyst reports. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 1.0 %

Shares of Novo Nordisk A/S stock opened at $87.19 on Friday. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market capitalization of $391.25 billion, a P/E ratio of 26.50, a PEG ratio of 0.90 and a beta of 0.42. The company’s fifty day moving average is $84.91 and its two-hundred day moving average is $105.07.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.